4.3 Article

Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis

Journal

ONCOTARGET
Volume 5, Issue 11, Pages 3472-3481

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.1927

Keywords

nc886; ESCC; CpG DNA methylation; tumor suppressor

Funding

  1. American Cancer Society [RSG-12-187-01 - RMC]
  2. National Institutes of Health [CA150229]
  3. National Cancer Center (at Korea) [1110260]
  4. NCI [CA016672]
  5. Korea Health Promotion Institute [1110260] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

nc886 (= vtRNA2-1 or pre-miR-886) is a recently discovered noncoding RNA that is a cellular PKR (Protein Kinase RNA-activated) ligand and repressor. nc886 has been suggested to be a tumor suppressor, solely based on its expression pattern and genomic locus. In this report, we have provided sufficient evidence that nc886 is a putative tumor suppressor in esophageal squamous cell carcinoma (ESCC). In 84 paired specimens from ESCC patients, nc886 expression is significantly lower in tumors than their normal adjacent tissues. More importantly, decreased expression of nc886 is significantly associated with shorter recurrence-free survival of the patients. Suppression of nc886 is mediated by CpG hypermethylation of its promoter, as evidenced by its significant negative correlation to nc886 expression in ESCC tumors and by induced expression of nc886 upon demethylation of its promoter. Knockdown of nc886 and consequent PKR activation induce FOS and MYC oncogenes as well as some inflammatory genes including oncogenic NF-kappa B. When ectopically expressed, nc886 inhibits proliferation of ESCC cells, further demonstrating that nc886 could be a tumor suppressor. All these findings implicate nc886 as a novel, putative tumor suppressor that is epigenetically silenced and regulates the expression of oncogenes in ESCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition

Jaffer A. Ajani, Yan Xu, Longfei Huo, Ruiping Wang, Yuan Li, Ying Wang, Melissa Pool Pizzi, Ailing Scott, Kazuto Harada, Lang Ma, Xiaodan Yao, Jiankang Jin, Wei Zhao, Xiaochuan Dong, Brian D. Badgwell, Namita Shanbhag, Ghia Tatlonghari, Jeannelyn Santiano Estrella, Sinchita Roy-Chowdhuri, Makoto Kobayashi, Jody V. Vykoukal, Samir M. Hanash, George Adrian Calin, Guang Peng, Ju-Seog Lee, Randy L. Johnson, Zhenning Wang, Linghua Wang, Shumei Song

Summary: YAP1 is highly upregulated in peritoneal carcinomatosis tumor cells, contributing to cancer stem cell properties and metastasis. Inhibition of YAP1 can significantly slow tumor growth and eliminate peritoneal carcinomatosis in preclinical models. Pharmacological inhibition of YAP1 can reduce cancer stem cell-like properties and suppress tumor growth, especially in combination with cytotoxic drugs in vivo models.
Article Gastroenterology & Hepatology

Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features

Changyu Zhu, Yu-Jui Ho, Marcela A. Salomao, Dianne H. Dapito, Alberto Bartolome, Robert F. Schwabe, Ju-Seog Lee, Scott W. Lowe, Utpal B. Pajvani

Summary: The study revealed that Notch activity characterizes a distinct molecular subtype of HCC in humans, associated with unique histology and prognosis. Sustained Notch signaling in chronic liver diseases can drive tumor formation without acquiring specific genomic driver mutations.

JOURNAL OF HEPATOLOGY (2021)

Article Oncology

Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy

Changhee Park, Kyeonghun Jeong, Joon-Hyeong Park, Sohee Jung, Jeong Mo Bae, Kwangsoo Kim, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Ju-Seog Lee, Dong-Wan Kim, Gyeong Hoon Kang, Doo Hyun Chung, Dae Seog Heo

Summary: The study demonstrated a negative correlation between overall methylation aberrancy and tumor immunogenicity, indicating the importance of methylation aberrancy for tumors to evade immune surveillance. This highlights the need for further development of methylation biomarkers in cancer research.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Article Biochemistry & Molecular Biology

Nc886, a Novel Suppressor of the Type I Interferon Response Upon Pathogen Intrusion

Yeon-Su Lee, Xiaoyong Bao, Hwi-Ho Lee, Jiyoung Joan Jang, Enkhjin Saruuldalai, Gaeul Park, Wonkyun Ronny Im, Jong-Lyul Park, Seon-Young Kim, Sooyong Shin, Sung Ho Jeon, Sangmin Kang, Hyun-Sung Lee, Ju-Seog Lee, Ke Zhang, Eun Jung Park, In-Hoo Kim, Yong Sun Lee

Summary: The noncoding RNA nc886 acts as a novel suppressor for the IFN-beta signaling and inflammation by inhibiting the activation of IRF3, NF-kappa B, and AP-1 through inhibiting PKR. This leads to decreased expression of IFN-beta and IFN-stimulated genes. Its role is to restrict the IFN-beta signaling from hyperactivation, which may explain the variability of innate immune responses to pathogens based on biological settings.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Gastroenterology & Hepatology

Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease

Ji H. Nahm, Hye S. Lee, Haeryoung Kim, Sun Y. Yim, Ji-hyun Shin, Jeong E. Yoo, Sang H. Ahn, Jin S. Choi, Ju-Seog Lee, Young N. Park

Summary: This study developed a nomogram for predicting late recurrence of hepatocellular carcinoma (HCC) based on clinicopathological and molecular factors. The combination of pSTAT3, pERK1/2 and SYK immunoexpression with high lobular inflammatory activity and cirrhosis was found to predict late HCC recurrence.

LIVER INTERNATIONAL (2021)

Review Oncology

An Overview of the Genomic Characterization of Hepatocellular Carcinoma

Sun Young Yim, Ju-Seog Lee

Summary: Tumor classifications based on alterations in the genome, epigenome, or proteome have shown promise in improving patient outcomes, especially with regards to personalized treatment. Understanding the molecular and genomic subtypes of hepatocellular carcinoma (HCC) is crucial for discovering new targets and biomarkers, and the development of new technical platforms for analyzing patient samples holds great potential for future advancements in treatment.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

Article Oncology

Midnolin Regulates Liver Cancer Cell Growth In Vitro and In Vivo

Soo-Mi Kweon, Gayeoun Kim, Yunseong Jeong, Wendong Huang, Ju-Seog Lee, Keane K. Y. Lai

Summary: Liver cancer, one of the deadliest cancers, may be influenced by the little-known gene midnolin, which has been found to correlate with poor prognosis in patients and may have a significant impact on liver cancer development.

CANCERS (2022)

Article Oncology

Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment

Hee-Jin Jang, Hyun-Sung Lee, Wendong Yu, Maheshwari Ramineni, Cynthia Y. Truong, Daniela Ramos, Taylor Splawn, Jong Min Choi, Sung Yun Jung, Ju-Seog Lee, Daniel Y. Wang, Joel M. Sederstrom, Massimo Pietropaolo, Farrah Kheradmand, Christopher Amos, Thomas M. Wheeler, R. Taylor Ripley, Bryan M. Burt

Summary: Comprehensive single-cell proteomics analyses reveal the role of tumor-associated macrophages in resistance to PD-1 blockade therapy in lung adenocarcinoma progression. The spatiotemporal evolution of tumor-associated macrophages in the tumor-immune micro-environment governs tumor response to immunotherapy. PD-1 expression in a tumor-promoting subtype of tumor-associated macrophages controls tumor progression and protects tumor cells.

CANCER RESEARCH (2022)

Article Oncology

A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma

Thinh T. Nguyen, Hyun-Sung Lee, Bryan M. Burt, Christopher Amos, Chao Cheng

Summary: This study found that gene signature scores were more prognostic than genomic mutations, mRNA, and protein expression in malignant pleural mesothelioma (MPM). High immune infiltration levels were associated with prolonged survival. The integrated model combining intrinsic and extrinsic features provided independent prognostic values in MPM.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors

Amanda M. Nash, Samira Aghlara-Fotovat, Bertha Castillio, Andrea Hernandez, Aarthi Pugazenthi, Hyun-Sung Lee, Hee-Jin Jang, Annie Nguyen, Alexander Lu, Bryan M. Burt, Ravi K. Ghanta, Omid Veiseh

Summary: The IL2 cytokine factories showed significant therapeutic efficacy in treating malignant mesothelioma in a mouse model, enhancing the effectiveness of therapy through activation of immune cells, and the safety and translatability of the treatment system were also validated.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma

Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni, Daniel Y. Wang, Daniela Ramos, Jong Min Choi, Taylor Splawn, Monica Espinoza, Michelle Almarez, Leandria Hosey, Eunji Jo, Susan Hilsenbeck, Christopher I. Amos, R. Taylor Ripley, Bryan M. Burt

Summary: This study compared the effects of monotherapy and combination therapy on pathological response and survival in resectable patients. The results showed that combination therapy can alter the immune microenvironment of malignant pleural mesothelioma tumors and improve overall survival.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Clinical Significance of Glycolytic Metabolic Activity in Hepatocellular Carcinoma

Joann Jung, Sowon Park, Yeonwoo Jang, Sung-Hwan Lee, Yun Seong Jeong, Sun Young Yim, Ju-Seog Lee

Summary: Hepatocellular carcinoma (HCC) is a common cancer that causes a large number of deaths worldwide. Metabolic reprogramming is a key feature of HCC, allowing cancer cells to meet the high energy demands for fast growth. By comparing genomic data from mice and humans, we identified three distinct metabolic subtypes of HCC and found clinical and molecular characteristics associated with each subtype. Notably, we discovered that the high metabolic subtype is resistant to immunotherapy and uncovered a potential mechanism for this resistance.

CANCERS (2023)

Letter Gastroenterology & Hepatology

Reply: Consensus subtypes of HCC associated with clinical outcomes and genomic phenotypes

Sun Young Yim, Ju-Seog Lee

HEPATOLOGY (2023)

Article Multidisciplinary Sciences

Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis

Younghun Y. Han, Jinyoung J. Byun, Catherine Zhu, Ryan R. Sun, Julia Y. Roh, Heather Cordell, Hyun-Sung A. Lee, Vikram R. Shaw, Sung Wook Kang, Javad Razjouyan, Matthew A. Cooley, Manal M. Hassan, Katherine A. Siminovitch, Trine Folseraas, David Ellinghaus, Annika Bergquist, Simon M. Rushbrook, Andre Franke, Tom H. Karlsen, Konstantinos N. Lazaridis, Katherine A. McGlynn, Lewis R. Roberts, Christopher Amos, Christoph Schramm, David Shapiro, Elizabeth Goode

Summary: This study used multitrait joint analyses to explore the genetic contribution and correlations between various clinical and epidemiological traits associated with PSC. Several new risk loci and potential susceptibility genes such as MANBA and IRF5 were identified, and in silico drug screening provided candidate agents for further investigation of pharmacological effects in PSC.

NATURE COMMUNICATIONS (2023)

No Data Available